文献速递骨显像与常规 SPECT核素与放射性配体治疗

「177Lu」Lu-P15-073(一种新型双膦酸盐放射性配体治疗剂)用于骨转移的剂量学、安全性和疗效的首次人体研究

First-in-human study of dosimetry, safety and efficacy for [177Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-10-18

本研究纳入10例经「99mTc」Tc-MDP骨显像确认骨转移的患者,单次给予「177Lu」Lu-P15-073(1225±84 MBq)治疗,行系列全身平面显像评估生物分布与剂量学,并通过血液生物标志物和疼痛评分评估安全性与疗效。结果显示药物在骨转移灶快速显著摄取,红骨髓吸收剂量为0.034±0.010 mSv/MBq,患者耐受良好,87.5%(7/8)患者疼痛评分显著降低。

要点

  • 「177Lu」Lu-P15-073在骨转移灶快速显著摄取,血液和其他器官摄取极少。
  • 红骨髓吸收剂量为0.034±0.010 mSv/MBq,归一化有效剂量为0.013±0.005 mSv/MBq。
  • 87.5%(7/8)患者疼痛评分(NRS)从5.1±2.3降至3.0±1.8。

核心结论

  • 单次治疗剂量的「177Lu」Lu-P15-073在骨转移中显示出安全性、剂量学和疗效,治疗耐受良好,无严重不良事件。
  • 这些发现提示「177Lu」Lu-P15-073有望成为一种新型骨转移放射性配体治疗剂。

研究设计与样本

  • 首次人体研究,纳入10例年龄35至75岁、经「99mTc」Tc-MDP骨显像确认骨转移的患者。
  • 患者接受单次剂量「177Lu」Lu-P15-073治疗,剂量为1225±84 MBq(33±2 mCi)。
  • 治疗前经「99mTc」Tc-MDP骨显像验证骨转移,治疗后14天内行系列全身平面显像监测生物分布。
  • 对主要器官和肿瘤病灶进行剂量学评估,并通过血液生物标志物和疼痛评分评估安全性。

主要发现

  • 系列全身平面显像显示「177Lu」Lu-P15-073在骨转移灶快速且大量蓄积,血液和其他器官摄取极少。
  • 关键器官红骨髓的吸收剂量为0.034±0.010 mSv/MBq,归一化有效剂量为0.013±0.005 mSv/MBq,与其他177Lu标记双膦酸盐相比明显较低。
  • 骨转移灶持续高摄取,肿瘤剂量升高(中位数3.12 Gy/GBq)。
  • 患者对「177Lu」Lu-P15-073治疗耐受良好,无新发副作用。
  • 87.5%(7/8)患者疼痛量表(数值评定量表,NRS)显著降低,从5.1±2.3降至3.0±1.8。

关键数值与推荐

  • 红骨髓吸收剂量为0.034±0.010 mSv/MBq。
  • 归一化有效剂量为0.013±0.005 mSv/MBq。
  • 肿瘤剂量中位数为3.12 Gy/GBq。
  • 疼痛评分(NRS)从5.1±2.3降至3.0±1.8,87.5%(7/8)患者出现显著降低。
  • 「99mTc」Tc-MDP的TBRmean与「177Lu」Lu-P15-073摄取相关(P < 0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bisphosphonates are pivotal in managing bone tumors by inhibiting bone resorption. This study investigates the therapeutic potential of [177Lu]Lu-P15-073, a novel bisphosphonate, for radioligand therapy (RLT) in bone metastases. METHODS: Ten patients (age 35 to 75) with confirmed bone metastases underwent therapy with a single dose of [177Lu]Lu-P15-073 (1,225 ± 84 MBq, or 33 ± 2 mCi). Prior to treatment, bone metastases were verified via [99mTc]Tc-MDP bone scans. Serial planar whole-body scans monitored biodistribution over a 14-day period. Dosimetry was assessed for major organs and tumor lesions, while safety was evaluated through blood biomarkers and pain scores. RESULTS: Serial planar whole-body scans demonstrated rapid and substantial accumulation of [177Lu]Lu-P15-073 in bone metastases, with minimal uptake in blood and other organs. The absorbed dose in the critical organ, red marrow, was measured at (0.034 ± 0.010 mSv/MBq), with a notably low normalized effective dose (0.013 ± 0.005 mSv/MBq) compared to other 177Lu-labeled bisphosphonates. Persistent high uptake in bone metastases was observed, resulting in elevated tumor doses (median 3.12 Gy/GBq). Patients exhibited favorable tolerance to [177Lu]Lu-P15-073 therapy, with no new instances of side effects. Additionally, 87.5% (7/8) of patients experienced a significant reduction in pain scale (numerical rating scale, NRS, from 5.1 ± 2.3 to 3.0 ± 1.8). The tumor-background ratio (TBRmean) of [99mTc]Tc-MDP correlated significantly with [177Lu]Lu-P15-073 uptake (P < 0.01), indicating its potential for prediction of absorbed dose. CONCLUSIONS: This study demonstrates the safety, dosimetry, and efficacy of a single therapeutic dose of [177Lu]Lu-P15-073 in bone metastases. The treatment was well-tolerated with no severe adverse events. These findings suggest that [177Lu]Lu-P15-073 holds promise as a novel RLT agent for bone metastases.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhao R, Lv J, Li M, et al. First-in-human study of dosimetry, safety and efficacy for [177Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases. Eur J Nucl Med Mol Imaging. 2024. PMID: 39419848. doi:10.1007/s00259-024-06942-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。